Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Crestor Plan: Drop 80 Mg, Submit Lower-Dose Data In Q1

Executive Summary

AstraZeneca's updated Crestor NDA will focus on doses of 40 mg and lower following a decision not to seek approval for the 80 mg strength of the cholesterol drug

You may also be interested in...



AstraZeneca Defends Crestor; Public Citizen Renews Call For Withdrawal

The post-marketing safety profile of Crestor is in line with the overall experience of the statin category, AstraZeneca said May 19 in response to a renewed request from Public Citizen for withdrawal of the cholesterol-lowering drug

AstraZeneca Defends Crestor; Public Citizen Renews Call For Withdrawal

The post-marketing safety profile of Crestor is in line with the overall experience of the statin category, AstraZeneca said May 19 in response to a renewed request from Public Citizen for withdrawal of the cholesterol-lowering drug

AstraZeneca Agrees To Limit Distribution, Promotion Of Crestor 40 Mg

AstraZeneca has agreed to an unusual distribution system for Crestor to limit use of the 40 mg dose of the statin

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel